CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

Researchers studied the progression-free and overall survival rates of patients with advanced melanoma after cessation of immune checkpoint inhibitor therapy.

Researchers used FAERS data to understand and identify adverse drug reactions associated with capmatinib intake, newly identifying ototoxicity as a possible reaction.

Findings seen in women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer.

Investigators examined the effect of immunosuppression on poor outcomes among patients with cutaneous squamous cell carcinoma.

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

The average number of industry-funded trials started per month was 135.8 before the IRA was passed and 83.6 after — a 38.4% decrease.

Although the mother and her breastmilk tested positive for CAR T cells, the baby did not, showing only normal T- and B-cell subsets.

A retrospective review of patients with cancer treated with ICIs identified patient education needs by frequency and severity of irAEs.

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Researchers studied the relationship between lymphovascular invasion and adverse outcomes in patients with cutaneous squamous cell carcinoma.

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.